Tectonic Therapeutic, Inc.
TECXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Tectonic Therapeutic, Inc. focuses on Biotechnology services and products. Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). The company carries a $517.6M market cap, placing it firmly in the small-cap category. It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
Market Cap
$517.6M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-5.86
EPS (TTM)
$-4.46
EPS (Fwd)
$-4.68
ROE
-31.4%
ROA
-20.7%
Cash
$236.9M
Total Debt
$4.6M
Free CF
-$44.7M
52W Change
21.1%
Annual Financials
Cash vs Debt
With $236.9M in cash and $4.6M in debt, TECX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$44.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -31.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Tectonic Therapeutic, Inc.'s trajectory.